Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $439000.0.

  • CytomX Therapeutics' Cash from Investing Activities fell 9758.37% to $439000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 13098.6%. This contributed to the annual value of $99.7 million for FY2024, which is 16616.93% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Cash from Investing Activities of $439000.0 as of Q3 2025, which was down 9758.37% from -$76.4 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Cash from Investing Activities peaked at $99.8 million during Q4 2022, and registered a low of -$146.6 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was $9.7 million (2021), whereas its average is $1.3 million.
  • In the last 5 years, CytomX Therapeutics' Cash from Investing Activities surged by 4084204.08% in 2022 and then tumbled by 1982418.48% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Cash from Investing Activities stood at -$245000.0 in 2021, then surged by 40842.04% to $99.8 million in 2022, then plummeted by 87.11% to $12.9 million in 2023, then rose by 17.64% to $15.1 million in 2024, then crashed by 97.1% to $439000.0 in 2025.
  • Its Cash from Investing Activities stands at $439000.0 for Q3 2025, versus -$76.4 million for Q2 2025 and $30.6 million for Q1 2025.